APA način citiranja (7. izdanje)

(15046889), K. E. H., (15046892), X. W., (15046895), J. S. R., (15046898), D. J. L., (15046901), N. E. S., (15046904), W. J. F., . . . (15046970), M. E. Y. (2025). Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.

Čikaški stil citiranja (17. izdanje)

(15046889), Katie E. Hebron, et al. Supplementary Data File S6 from The Combination of Trametinib and Ganitumab Is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models. 2025.

MLA način citiranja (9. izdanje)

(15046889), Katie E. Hebron, et al. Supplementary Data File S6 from The Combination of Trametinib and Ganitumab Is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models. 2025.

Upozorenje: Ovi citati možda nisu uvijek 100% točni.